With drug Empagliflozin going off patent, doctors look forward to price reduction, benefitting diabetic, heart and kidney patients
Empagliflozin patent expiration in India leads to affordable treatment for diabetes, heart failure, and kidney disease.
Frontiers3y
Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
Background: Dipeptidylpeptidase-4 inhibitors (DPP-4i′s) are considered to be safe for patients with type 2 diabetes mellitus (T2DM). However, little is known about drug–drug interactions between ...